|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Colorectal cancer:Metastases to a single organ显示文摘Colorectal cancer(CRC) is a common malignancy worldwide. In CRC patients, metastases are the main cause of cancer-related mortality. In a group of metastatic CRC patients, the metastases are limited to a single site(solitary organ); the liver and lungs are the most commonly involved sites. When metastatic disease is limited to the liver and/or lungs, the resectability of the metastatic lesions will dictate the management approach and the outcome. Less commonly, the site of solitary organ CRC metastasis is the peritoneum. In these patients, cytoreduction followed by hyperthermic intraperitoneal chemotherapy may improve the outcome. Rarely, CRC involves other organs, such as the brain, bone, adrenals and spleen, as the only site of metastatic disease. There are limited data to guide clinical practice in these cases. Here, we have reviewed the disease characteristics, management approaches and prognosis based on the metastatic disease site in patients with CRC with metastases to a single organ. | Sina Vatandoust Timothy J Price Christos S Karapetis | 2015 | World Journal of Gastroenterology2015，21，41： | 30 |
| 2 | Management of gastric cancer in Asia: resource-stratified guidelines显示文摘 | Lin Shen Yan-Shen Shan Huang-Ming Hu Timothy J Price Bhawna Sirohi Kun-Huei Yeh Yi-Hsin Yang Takeshi Sano Han-Kwang Yang Xiaotian Zhang Sook Ryun Park Masashi Fujii Yoon-Koo Kang Li-Tzong Chen | 2013 | Lancet Oncology2013，，12： | 5 |
| 3 | Brain metastasis in advanced colorectal cancer: results from the South Australian metastatic colorectal cancer (SAmCRC) registry显示文摘Objective:Brain metastasis is considered rare in metastatic colorectal cancer(mCRC);thus,surveillance imaging does not routinely include the brain.The reported incidence of brain metastases ranges from 0.6% to 3.2%.Methods:The South Australian mCRC Registry(SAmCRC)was analyzed to assess the number of patients presenting with brain metastasis during their lifetime.Due to small numbers,a descriptive analysis is presented.Results:Only 59 patients of 4,100 on the registry at the time of analysis had developed brain metastasis(1.4%).The clinical characteristics of those with brain metastasis were as follows:the median age was 65.3 years and 51% were female.Where the V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog(KRAS)mutation status of the tumor was known,the majority harbored a KRAS mutation(55%);31(53%)underwent craniotomy and 55(93%)underwent whole-brain radiotherapy.The median survival time from diagnosis of brain metastasis was 4.2 months(95% confidence interval 2.9–5.5).Patients who underwent craniotomy and radiotherapy had superior survival compared to those who underwent whole-brain radiotherapy(8.5 months vs.2.2 months,respectively).Data from the SAmCRC(a population-based registry)confirm that brain metastases are rare and the median time to development is approximately 2 years.Conclusions:Brain metastasis is a rare outcome in advanced CRC.Patients within the registry tended to be female,young in age,and harbored with higher rates of KRAS mutations.Whether routine surveillance brain scanning should be considered remains controversial given the relative rarity of developing brain metastases in mCRC and ultimately,most patients with central nervous system involvement die from their extracranial disease. | Gonzalo Tapia Rico Timothy J. Price Christos Karapetis Cynthia Piantadosi Rob Padbury Amitesh Roy Guy Maddern James Moore Scott Carruthers David Roder Amanda R. Townsend | 2017 | Cancer Biology & Medicine2017，14，4： | 3 |
| 4 | Biologic therapies in the metastatic colorectal cancer treatment continuum – Applying current evidence to clinical practice显示文摘 | Marc Peeters Timothy Price | 2011 | Cancer Treatment Reviews2011，，5： | 3 |
| 5 | Gastrointestinal perforation in metastatic colorectal cancer patients with peritoneal metastases receiving bevacizumab显示文摘AIM:To investigate the safety and efficacy of adding bevacizumab to first-line chemotherapy in metastatic colorectal cancer patients with peritoneal disease.METHODS:We compared rates of gastrointestinal perforation in patients with metastatic colorectal cancer and peritoneal disease receiving first-line chemotherapy with and without bevacizumab in three distinct cohorts:(1) the AGITG MAX trial(Phase Ⅲ randomised clinical trial comparing capecitabine vs capecitabine and bevacizumab vs capecitabine,bevacizumab and mitomycin C);(2) the prospective Treatment of Recurrent and Advanced Colorectal Cancer(TRACC) registry(any first-line regimen ± bevacizumab);and(3) two cancer centres in New South Wales,Australia [Macarthur Cancer Therapy Centre and Liverpool Cancer Therapy Centre(NSWCC) from January 2005 to Decenber 2012,(any first-line regimen ± bevacizumab).For the AGITG MAX trial capecitabine was compared to the other two arms(capecitabine/bevacizumab and capecitabine/bevacizumab/mitomycin C).In the AGITG MAX trial and the TRACC registry rates of gastrointestinal perforation were also collected in patients who did not have peritoneal metastases.Secondary endpoints included progression-free survival,chemotherapy duration,and overall survival.Time-toevent outcomes were estimated using the Kaplan-Meier method and compared using the log-rank test.RESULTS:Eighty-four MAX,179 TRACC and 69 NSWCC patients had peritoneal disease.There were no gastrointestinal perforations recorded in either the MAX subgroup or the NSWCC cohorts.Of the patients without peritoneal disease in the MAX trial,4/300(1.3%) in the bevacizumab arms had gastrointestinal perforations compared to 1/123(0.8%) in the capecitabine alone arm.In the TRACC registry 3/126(2.4%) patients who had received bevacizumab had a gastrointestinal perforation compared to 1/53(1.9%) in the chemotherapy alone arm.In a further analysis of patients without peritoneal metastases in the TRACC registry,the rate of gastrointestinal perforations was 9/369(2.4%) in the chemotherapy/bevacizumab group and 5/177(2.8%) in the chemotherapy alone group.The addition of bevacizumab to chemotherapy was associated with improved progression-free survival in all three cohorts:MAX 6.9 m vs 4.9 m,HR = 0.64(95%CI:0.42-1.02);P = 0.063;TRACC 9.1 m vs 5.5 m,HR = 0.61(95%CI:0.37-0.86);P = 0.009;NSWCC 8.7 m vs 6.8 m,HR = 0.75(95%CI:0.43-1.32);P = 0.32.Chemotherapy duration was similar across the groups.CONCLUSION:Patients with peritoneal disease do not appear to have an increased risk of gastrointestinal perforations when receiving first-line therapy with bevacizumab compared to systemic therapy alone. | Aflah Roohullah Hui-Li Wong Katrin M Sjoquist Peter Gibbs Kathryn Field Ben Tran Jeremy Shapiro Joe Mckendrick Desmond Yip Louise Nott Val Gebski Weng Ng Wei Chua Timothy Price Niall Tebbutt Lorraine Chantrill | 2015 | World Journal of Gastroenterology2015，21，17： | 3 |
| 6 | Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study显示文摘 | Timothy J Price Marc Peeters Tae Won Kim Jin Li Stefano Cascinu Paul Ruff Atilli Satya Suresh Anne Thomas Sergei Tjulandin Kathy Zhang Swaminathan Murugappan Roger Sidhu | 2014 | Lancet Oncology2014，，6： | 2 |
| 7 | Epidemiology of neuroendocrine cancers in an Australian population显示文摘 | Colin Luke Timothy Price Amanda Townsend Christos Karapetis Dusan Kotasek Nimit Singhal Elizabeth Tracey David Roder | 2010 | Cancer Causes & Control2010，，6： | 2 |
| 8 | Prospective multicentre randomised controlled trial of early enteral nutrition for patients undergoing major upper gastrointestinal surgical resection显示文摘 | Rachael Barlow Patricia Price Thomas D. Reid Sarah Hunt Geoffrey W.B. Clark Timothy J. Havard Malcolm C.A. Puntis Wyn G. Lewis | 2011 | Clinical Nutrition2011，，5： | 2 |
| 9 | Role of metastable phases in the spontaneous precipitation of calcium carbonate显示文摘 | John R Clarkson Timothy J Price Christopher J Adms | 1992 | Chem Soc Faraday Trans1992，88，2： | 1 |
| 10 | Aureobasidium pullulans as a source of liamocins (heavy oils) with anticancer activity显示文摘 | Pennapa Manitchotpisit Ramida Watanapoksin Neil P. J. Price Kenneth M. Bischoff Malatee Tayeh Sudarat Teeraworawit Saranya Kriwong Timothy D. Leathers | 2014 | World Journal of Microbiology and Biotechnology2014，，： | 1 |
| 11 | A comparison of yarn evenness and imperfection data显示文摘 | John B Price Timothy A Calamari William R Meredith | 2002 | Textile R J2002，72，9： | 1 |
| 12 | Liver only metastatic disease in patients with metastatic colorectal cancer: Impact of surgery and chemotherapy显示文摘 | Sunita Padman Robert Padbury Carol Beeke Christos S. Karapetis Sarwan Bishnoi Amanda R. Townsend Guy Maddern Timothy J. Price | 2013 | Acta Oncologica2013，，8： | 1 |
| 13 | A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma显示文摘 | Karl D. Lewis William A. Robinson Michael J. Millward Alex Powell Timothy J. Price Damien B. Thomson Euan T. Walpole Andrew M. Haydon Brian R. Creese Kaye L. Roberts John R. Zalcberg Rene Gonzalez | 2008 | Investigational New Drugs2008，，1： | 1 |
| 14 | Risk Factors for Drug‐resistant Streptococcus pneumoniae and Antibiotic Prescribing Practices in Outpatient Community‐acquired Pneumonia显示文摘 | Timothy C. Jenkins Joy Sakai Bryan C. Knepper Claire J. Swartwood Jason S. Haukoos Jeremy A. Long Connie S. Price William J. Burman | 2012 | Academic Emergency Medicine2012，，6： | 1 |
| 15 | Risk Factors for Drug‐resistant Streptococcus pneumoniae and Antibiotic Prescribing Practices in Outpatient Community‐acquired Pneumonia显示文摘 | Timothy C. Jenkins Joy Sakai Bryan C. Knepper Claire J. Swartwood Jason S. Haukoos Jeremy A. Long Connie S. Price William J. Burman | 2012 | Academic Emergency Medicine2012，，6： | 1 |
| 16 | Markers of cholesterol transport are associated with amyloid deposition in the brain显示文摘 | Timothy M. Hughes Oscar L. Lopez Rhobert W. Evans M. Ilyas Kamboh Jeff D. Williamson William E. Klunk Chester A. Mathis Julie C. Price Ann D. Cohen Beth E. Snitz Steven T. DeKosky Lewis H. Kuller | 2014 | Neurobiology of Aging2014，，4： | 1 |
| 17 | Rising incidence of early‐onset colorectal cancer in A ustralia over two decades: Report and review显示文摘 | Joanne P Young Aung Ko Win Christophe Rosty Ingrid Flight David Roder Graeme P Young Oliver Frank Graeme K Suthers Peter J Hewett Andrew Ruszkiewicz Ehud Hauben Barbara‐Ann Adelstein Susan Parry Amanda Townsend Jennifer E Hardingham Timothy J Price | 2015 | J Gastroenterol Hepatol2015，，： | 1 |
| 18 | Prospective multicentre randomised controlled trial of early enteral nutrition for patients undergoing major upper gastrointestinal surgical resection显示文摘 | Rachael Barlow Patricia Price Thomas D. Reid Sarah Hunt Geoffrey W.B. Clark Timothy J. Havard Malcolm C.A. Puntis Wyn G. Lewis | 2011 | Clinical Nutrition2011，，5： | 1 |
| 19 | Microstructure and Wear Properties of Aluminum/Aluminum-Silicon Composite Coatings Prepared by Cold Spraying显示文摘 | Srinivasa R Bakshi Di Wang Timothy Price | | 0，，： | 1 |
| 20 | Role of metastable phases in the spontaneous precipitation of calcium carbonate显示文摘 | John R Clarkson Timothy J Price Christopher J Adms | 1992 | Chem Soc Faraday Trans1992，88，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员